Target trial emulation of first-line ribociclib versus palbociclib in hormone receptor-positive, HER2-negative metastatic breast cancer: a comparative effectiveness study.
- DOI
- 10.1007/s12282-026-01921-9
- Published
- 2026 Nov
- Container
- Breast cancer (Tokyo, Japan)
- Publisher
- Not recorded
- Open access
- no
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1007/s12282-026-01921-9,
title = {Target trial emulation of first-line ribociclib versus palbociclib in hormone receptor-positive, HER2-negative metastatic breast cancer: a comparative effectiveness study.},
author = {Zhang X and Chen PH and Chang WC and Jhou HJ and Chen HY and Kao LT and Hsieh TY and Dai MS and Xiao N and Lee CH},
year = {2026},
journal = {Breast cancer (Tokyo, Japan)},
doi = {10.1007/s12282-026-01921-9},
url = {https://doi.org/10.1007/s12282-026-01921-9}
}RIS
TY - JOUR TI - Target trial emulation of first-line ribociclib versus palbociclib in hormone receptor-positive, HER2-negative metastatic breast cancer: a comparative effectiveness study. AU - Zhang X AU - Chen PH AU - Chang WC AU - Jhou HJ AU - Chen HY AU - Kao LT AU - Hsieh TY AU - Dai MS AU - Xiao N AU - Lee CH PY - 2026 JO - Breast cancer (Tokyo, Japan) DO - 10.1007/s12282-026-01921-9 UR - https://doi.org/10.1007/s12282-026-01921-9 ER -
APA
X, Z., PH, C., WC, C., HJ, J., HY, C., LT, K., TY, H., MS, D., N, X., & CH, L. (2026). Target trial emulation of first-line ribociclib versus palbociclib in hormone receptor-positive, HER2-negative metastatic breast cancer: a comparative effectiveness study.. Breast cancer (Tokyo, Japan). https://doi.org/10.1007/s12282-026-01921-9
Source records
- pubmed · retrieved 2026-11-10T11:07:08.666Z
- europe-pmc · retrieved 2026-11-10T11:07:08.664Z